Pulmonx (NASDAQ:LUNG) Insider Sells $10,468.80 in Stock

Pulmonx Corporation (NASDAQ:LUNG – Get Free Report) insider Geoffrey Beran Rose sold 6,543 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $1.60, for a total value of $10,468.80. Following the completion of the transaction, the insider owned 379,788 shares in the company, valued at approximately $607,660.80. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Pulmonx Trading Down 4.0%

Shares of NASDAQ LUNG opened at $1.66 on Thursday. The stock’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $4.22. Pulmonx Corporation has a 52-week low of $1.47 and a 52-week high of $9.37. The stock has a market capitalization of $67.64 million, a P/E ratio of -1.16 and a beta of 0.43. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54.

Pulmonx (NASDAQ:LUNG – Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%.The firm had revenue of $23.86 million for the quarter, compared to analysts’ expectations of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. On average, analysts anticipate that Pulmonx Corporation will post -1.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

---

---

Several analysts have issued reports on the company. Wells Fargo & Company cut their price objective on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Stifel Nicolaus dropped their price target on Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. D. Boral Capital dropped their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. Finally, Lake Street Capital dropped their price target on Pulmonx from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.66.

Check Out Our Latest Report on Pulmonx

Hedge Funds Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LUNG. Corton Capital Inc. bought a new position in Pulmonx during the 2nd quarter valued at $32,000. R Squared Ltd bought a new stake in shares of Pulmonx during the 2nd quarter worth $41,000. BNP Paribas Financial Markets bought a new stake in shares of Pulmonx during the 4th quarter worth $43,000. Bank of Montreal Can bought a new stake in shares of Pulmonx during the 2nd quarter worth $53,000. Finally, ProShare Advisors LLC bought a new stake in shares of Pulmonx during the 4th quarter worth $72,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

(Get Free Report)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].